Biotechnology firm Immunomic Therapeutics has partnered with EpiVax and PharmaJet to develop a vaccine candidate against Covid-19 infection.

Immunomic will leverage its UNITE platform, along with its partners’ immunology and vaccine delivery expertise to rapidly create a nucleic acid vaccine candidate.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Previously, UNITE platform was used to develop vaccine candidates for rabies, yellow fever, dengue fever, hepatitis C and also SARS, which is similar to the novel coronavirus.

Immunomic Therapeutics CEO Dr William Hearl said: “We believe that our UNITE platform, which has shown promising results in infectious disease applications, is well-suited to develop novel vaccines for coronaviruses.

“To rapidly advance our Covid-19 programme, we are excited to collaborate with EpiVax, PharmaJet and our academic and strategic partners to explore ways to flatten the curve and prevent the spread of this deadly virus.”

The partners will combine Immunomic’s UNITE platform with EpiVax’s in silico T cell epitope prediction tool and PharmaJet’s Tropis Needle-free Injection System.

PharmaJet’s system is designed to accurately target delivery to the intradermal tissue layer.

The combined technologies are expected to help create a vaccine that could induce broad and potent immune responses.

In addition, the aim is a product that is feasible for rapid-responses, scalable, thermostable, safe and can be administered by healthcare professionals.

Immunomic also intends to consider grant initiatives via the US government,  companies, institutions, non-profit organisations and investigators to further its efforts against Covid-19.

EpiVax CEO Dr Annie De Groot said: “We believe that the UNITE platform, combined with epitopes that have been carefully triaged by EpiVax’s advanced computational tools, will generate a highly effective immune response against the pathogen that causes Covid-19, while reducing off-target effects.”

Last month, EpiVax partnered with University of Georgia (UGA) researcher Ted Ross to develop Covid-19 a vaccine.